Choosing The Right Solid Form

Small-molecule drug development hinges heavily on choosing the right crystal form. Because identical chemical compositions can pack into distinct polymorphs, hydrates, or solvates, physical properties such as solubility, stability, and bioavailability often vary dramatically. Overlooking solid-state variations early can trigger costly reformulation setbacks or regulatory delays down the line. Implementing a phase-appropriate screening strategy—from enabling screens in early preclinical stages to extensive profiling before regulatory filing—allows researchers to map out potential solid forms, control manufacturing risks, and strengthen intellectual property positions. By combining rigorous experimental screening with advanced structural informatics, development teams can confidently select the most stable, robust solid form for commercial success.

To explore comprehensive screening methodologies, phase-by-phase checklists, and real-world case studies, access the full guide today.